Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

753
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
753
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

563
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
563
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

215
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
215
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

189
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
189

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Molecular Insights into the Dual Mechanism of Bepristat 2a on Protein Disulfide Isomerase (PDI) Activity.

The journal of physical chemistry letters·2025
Same author

Modifying Antimicrobial Peptides with Albumin-Binding Molecules Enhances Membrane-Disrupting Efficacy by Modulating the Secondary Structure.

Journal of medicinal chemistry·2025
Same author

Recent Advances in Clinically Used and Trialed Photosensitizers for Antitumor Photodynamic Therapy.

Molecular pharmaceutics·2025
Same author

Discovery of the Low-Hemorrhagic Antithrombotic Effect of Montelukast by Targeting FXIa in Mice.

Arteriosclerosis, thrombosis, and vascular biology·2025
Same author

Development of a recombinant Ang1 variant with enhanced Tie2 binding and its application to attenuate sepsis in mice.

Science advances·2025
Same author

Antitumor Activity and Mechanistic Insights of a Mitochondria-Targeting Cu(I) Complex.

Journal of medicinal chemistry·2024

Related Experiment Video

Updated: Jul 20, 2025

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.8K

Polyphosphate as an antithrombotic target and hemostatic agent.

Ruoyu Chen1, Mingdong Huang1,2, Peng Xu1

  • 1College of Biological Science and Engineering, Fuzhou University, Fuzhou, Fujian, 350108, P. R. China. HMD_lab@fzu.edu.cn.

Journal of Materials Chemistry. B
|August 3, 2023
PubMed
Summary

Polyphosphate (PolyP) is a key regulator of blood clotting and inflammation. Targeting PolyP offers a novel low-hemorrhagic antithrombotic strategy and aids in developing effective hemostatic materials.

More Related Videos

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel
07:26

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Published on: June 29, 2015

17.7K
Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery
12:27

Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery

Published on: August 22, 2016

7.7K

Related Experiment Videos

Last Updated: Jul 20, 2025

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.8K
Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel
07:26

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Published on: June 29, 2015

17.7K
Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery
12:27

Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery

Published on: August 22, 2016

7.7K

Area of Science:

  • Biochemistry
  • Hematology
  • Materials Science

Background:

  • Polyphosphate (PolyP) is a polymer of phosphate units found in various organisms.
  • PolyP plays roles in coagulation and inflammation, with chain length influencing its effects.
  • Short-chain PolyP is released by activated platelets and neutrophils, initiating coagulation.

Purpose of the Study:

  • To review PolyP as a low-hemorrhagic antithrombotic target.
  • To summarize the development of PolyP-based hemostatic materials.

Main Methods:

  • Review of current scientific literature on PolyP.
  • Analysis of PolyP's role in thrombosis and hemostasis.
  • Examination of targeting strategies and material applications.

Main Results:

  • PolyP is a promising antithrombotic target, suppressing thrombosis without affecting hemostasis.
  • Long-chain PolyP shows greater procoagulant and proinflammatory effects than short-chain PolyP.
  • PolyP is effectively targeted by cationic polymers and polyphosphatases.
  • PolyP incorporation into wound dressings enhances hemostasis.

Conclusions:

  • PolyP neutralization represents a viable low-hemorrhagic antithrombotic approach.
  • PolyP-based materials show potential for wound healing and blood control.
  • Further research into PolyP's biological roles and therapeutic applications is warranted.